NCT04675502

Brief Summary

Scleroderma, also called systemic sclerosis (SSc); It is a heterogeneous multiorgan disease of unknown etiology characterized by vasculopathy, autoimmunity and fibrous tissue. It is stated in studies that cardiac and pulmonary systems are affected in patients with SSc and these effects affect the aerobic capacity, physical functions and quality of life of patients negatively by disrupting their pulmonary and musculoskeletal functions. However, considering the treatment approaches in scleroderma patients, the number of studies evaluating the effectiveness of pulmonary rehabilitation and exercises is limited. Therefore, the purpose of our study; Comparison of the effects of a supervised exercise program and a home exercise program in patients with Systemic Sclerosis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
37

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 10, 2018

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

November 25, 2020

Completed
24 days until next milestone

First Posted

Study publicly available on registry

December 19, 2020

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 13, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 13, 2021

Completed
Last Updated

April 14, 2021

Status Verified

February 1, 2021

Enrollment Period

2.8 years

First QC Date

November 25, 2020

Last Update Submit

April 13, 2021

Conditions

Outcome Measures

Primary Outcomes (8)

  • Change in Forced Vital Capacity

    Pulmonary function test was applied by Sensor Medics Vmax 22 0,6-2B version spirometer (ERS 1993 Uptake + Zapleta, SensorMedics, Inc, Anaheim, CA, USA). Forced vital capacity (FVC) percent was recorded according to the American Thoracic Society (ATS) / European Respiratory Society (ERS) criteria

    Baseline, 12th week

  • Change in Forced Expiratory Volume in One Second

    Pulmonary function test was applied by Sensor Medics Vmax 22 0,6-2B version spirometer (ERS 1993 Uptake + Zapleta, SensorMedics, Inc, Anaheim, CA, USA). Forced expiratory volume in one second (FEV1) percent was recorded according to the American Thoracic Society (ATS) / European Respiratory Society (ERS) criteria

    Baseline, 12th week

  • Change in Forced expiratory volume in one second / Forced vital capacity

    Pulmonary function test was applied by Sensor Medics Vmax 22 0,6-2B version spirometer (ERS 1993 Uptake + Zapleta, SensorMedics, Inc, Anaheim, CA, USA). Forced expiratory volume in one second (FEV1)/Forced vital capacity (FVC) ratio percent was recorded according to the American Thoracic Society (ATS) / European Respiratory Society (ERS) criteria

    Baseline, 12th week

  • Change in diffusion capacity

    Single breath carbon monoxide method was used in diffusion capacity for carbon monoxide (DLCO) percent measurement

    Baseline, 12th week

  • Change in Maximal Expiratory Pressure

    Electronic mouth pressure measuring device was used for respiratory muscle strength. Maximal expiratory pressure (MEP) was measured. MEP was measured from total lung capacity performing a maximal expiratory effort against an occluded airway. MEP measurements was repeated three times, and the maximum percent achieved was recorded

    Baseline, 12th week

  • Change in Maximal Inspiratory Pressure

    Electronic mouth pressure measuring device was used for respiratory muscle strength. Maximal inspiratory pressure (MIP) was measured. MIP was measured from residual volume upon a maximal inspiratory effort against an occluded airway. occluded airway. MIP measurements was repeated three times, and the maximum percent achieved was recorded.

    Baseline, 12th week

  • Change in functional capacity

    Six-minute walk test (6MWT) is a valid, reliable and useful test for assessing functional capacity of patients. This test assesses distance walked over 6 minutes as a sub maximal test of aerobic capacity/endurance.

    Baseline, 12th week

  • Change in peripheral muscle strength

    The Jamar Handgrip Dynamometer is an instrument for measuring the maximum isometric strength of the hand and forearm muscles. Quadriceps isometric muscle strength is measured with a Hand Held Dynamometer.

    Baseline, 12th week

Secondary Outcomes (5)

  • Change in severity of dyspnoea

    Baseline, 12th week

  • Change in fatigue

    Baseline, 12th week

  • Change in quality of life:Health Assessment Questionnaire Disability Index

    Baseline, 12th week

  • Change in quality of life: Scleroderma Health Assessment Questionnaire

    Baseline, 12th week

  • Change in quality of life: Short Form-36 Quality of Life Questionnaire

    Baseline, 12th week

Study Arms (2)

Supervised Exercise Group

EXPERIMENTAL

Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In this loading program; respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes is taken. Stretching exercises are done during the cooling period. This group was included in an exercise program 2 days a week, 45-90 minutes, for 12 weeks, accompanied by a specialist physiotherapist to the pulmonary rehabilitation unit in the chest diseases ward.

Other: supervised Exercise training

Home Exercise Group

EXPERIMENTAL

For patients to do at home (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), sitting and standing exhaustion, and brisk walking to reach 60-85% of the person's maximum heart rate.)), exercises is taught. Patients were asked to do the exercises at home for 45-90 minutes, 2 days a week, for 12 weeks. Participants of the control group are contacted every two weeks via communication methods such as e-mail, message and telephone conversation.Exercise diary is given to all patients and is taken from them at the end of the study.

Other: home exercise trainig

Interventions

warm-up, loading (respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes), cooling, and relaxation exercises

Supervised Exercise Group

Warm-up, loading (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), cooling and relaxation exercises

Home Exercise Group

Eligibility Criteria

Age35 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Stable clinical status for at least two weeks
  • Walking independently
  • Volunteer for research study

You may not qualify if:

  • Having unstable angina
  • Having uncontrolled hypertension
  • Having hemodynamic instability
  • Participating in any exercise program in the last six months
  • Having a major orthopedic or neurological problem that limits functionality

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dokuz Eylül Üniversitesi School of Physical Therapy and Rehabilitation

Izmir, İzmir, Turkey, 35340, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Scleroderma, Systemic

Condition Hierarchy (Ancestors)

Connective Tissue DiseasesSkin and Connective Tissue DiseasesSkin Diseases

Study Officials

  • Hazal Yakut, PT,MSc

    Dokuz Eylul University

    PRINCIPAL INVESTIGATOR
  • Sevgi Özalevli, PT,PhD

    Dokuz Eylul University

    STUDY DIRECTOR
  • Gerçek Can, MD

    Dokuz Eylul University

    STUDY CHAIR
  • Aylin Özgen Alpaydın, MD

    Dokuz Eylul University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

November 25, 2020

First Posted

December 19, 2020

Study Start

June 10, 2018

Primary Completion

April 13, 2021

Study Completion

April 13, 2021

Last Updated

April 14, 2021

Record last verified: 2021-02

Locations